FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 355:2791-2792 December 28, 2006 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bennett, J. E. PubMed Citation

To the Editor: Bennett (Sept 14 issue)¹ did not mention voriconazole as an option for the treatment of candidemia in adults without neutropenia. However, in December 2005, on the basis of a randomized, open-label, comparative, multicenter study involving 422 patients worldwide,² the Food and Drug Administration approved the use of voriconazole for treating this infection. In this study, voriconazole was shown to be as effective as a regimen of amphotericin B followed by fluconazole. Treatment with voriconazole was better tolerated, and resulted in negative blood cultures as quickly as did treatment with amphotericin B and fluconazole.

Voriconazole has potent activity . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.